Fusiform Aneurysm of the Vertebrobasilar Arterial System
Henry C. Echiverri, MD, Frank A. Rubino, MD, Sudha R. Gupta, MD, and Meena Gujrati, MD We retrospectively evaluated the clinical features and therapeutic outcomes in 13 consecutive patients with the diagnosis of fusiform aneurysm of the vertebrobasilar system. Four patients (31%) presented with compressive symptoms and 10 (77%) with ischemic symptoms; one patient presented with both types of symptoms. No patient presented with rupture of the fusiform aneurysm. Based on the attending physician's choice, treatment included antiplatelet therapy in five patients, anticoagulation in seven, and no medication in one. Five patients died, four treated with antiplatelet agents and one not treated with any medication. The cause of death was progressive brainstem ischemia in three, sepsis in one, and gastrointestinal bleeding in one patient. All seven patients who received anticoagulants were alive, with no recurrence of symptoms or hemorrhagic complications after a mean follow-up period of 18 months. Based on previous and current series, we conclude that rupture of fusiform aneurysms is rare. Our results suggest a more favorable outcome in the management of these aneurysms with anticoagulation therapy to prevent progressive thrombosis and embolization. (Stroke 1989;20:1741-1747) I ntracranial aneurysms can be classified as saccular aneurysms or fusiform aneurysms using shape as a criterion. The developmental origin of saccular aneurysms as due to a defect in the elastic and muscular coats of blood vessels has been widely accepted. 1 -3 Fusiform aneurysms, on the other hand, have been associated with atherosclerotic processes so that the term "atherosclerotic aneurysm" has been used interchangeably. 4 -6 Because of the elongated and tortuous shapes of fusiform aneurysms, "dolichoectasia" is another term that has been used to describe them. 4 Review of previous studies indicates that fusiform aneurysms have been most frequently associated with compression, ischemia, or both and rarely with rupture. 5 -8 Various articles have described the clinical course of fusiform aneurysms, 5 -7 ' 9 ' 10 most in the vertebrobasilar system. However, none of these articles dealt with the aspect of treatment outcome. Only that of Nishizaki et al 5 comes close to hinting at the benefit of antiplatelet therapy; however, no justification was offered. Accordingly, we studied fusiform aneurysms of the vertebrobasilar system in 13 patients. We describe the clinical signs and symptoms and the outcome and discuss the therapeutic options.
Subjects and Methods
We studied 13 consecutive patients with the diagnosis of fusiform aneurysm seen at Hines Veterans Administration Hospital (Neurology Service), Hines, Illinois, between July 1980 and June 1988. The diagnosis was made by computed tomography (CT) of the head, cerebral angiography, or magnetic resonance imaging (MRI). Fusiform aneurysm was defined as a fusiform and segmental dilatation and tortuosity of a blood vessel in the vertebrobasilar system. The medical records were reviewed to determine the presentation, clinical course, and therapy of fusiform aneurysm. Postmortem findings were reviewed for two patients. Table 1 summarizes the clinical features of all 13 patients. Their ages ranged from 46 to 81 (mean 67) years old. There were two women and 11 men.
Results
The presenting features were categorized as compressive (due to mass effect of the ectatic vessel) or ischemic (due to thrombosis or embolization of vessels) ( Table 2 ). The duration of symptoms before diagnosis varied from 2 days to 3 years (mean 20 months for compressive symptoms and 5 months for ischemic symptoms). Compressive symptoms occurred in four patients (31%) and included cranial nerve involvement in three and hydrocephalus in Fusiform aneurysm was best visualized on CT scan with contrast infusion (Figure 1) . Occasionally, the ectatic vessel attained giant proportions, being large enough to cause a mass effect and obstruct the fourth ventricle, causing hydrocephalus. Cerebral angiography in six patients demonstrated a fusiform dilatation of the vessel (Figure 2) . In two patients, concomitant ectasia of the carotid circulation was also seen. MRI was obtained in two patients, and the ectatic vessel was demonstrated as a negative signal. Figure 3 is the MRI of Case 12, which also shows thalamic infarction.
After the initial presentation, before the diagnosis of fusiform aneurysm, 9 patients were treated with antiplatelet medication; the dosage of aspirin ranged from 325 mg/day (one tablet) to 1,300 mg/day (two tablets twice a day). After the diagnosis was made, five patients were maintained on antiplatelet therapy and seven were treated with an anticoagulant (warfarin) to maintain a prothrom- bin time of 1.5xcontrol. The treatment choice was the attending physician's decision. One patient did not receive any antiplatelet or anticoagulant therapy before or after the diagnosis due to the presence of gastrointestinal (GI) malignancy. One patient receiving aspirin both before and after the diagnosis also had a ventricular peritoneal shunt placed for hydrocephalus.
Outcome and follow-up status of all patients are summarized in Table 3 . Five patients died, two of brainstem infarction, one of hydrocephalus with sepsis, one of brainstem infarction and hydrocephalus, and one of GI bleeding. The remaining eight patients were alive with various residual deficits and had no recurrence or progression of symptoms. Seven of these eight patients received anticoagulant therapy, and one (Case 5) was not treated with anticoagulants due to the presence of concomitant carotid artery ectasia. The duration of follow-up after the diagnosis ranged from 9 to 36 (mean 18) months for the eight survivors. During the followup period, hemorrhagic complications from therapy, rupture of the fusiform aneurysm, or recurrent ischemia were not present.
Postmortem examination was available in two patients. Figure 4 illustrates the thrombosed aneurysm and the extensive pontine infarction with demyelination in Case 1. The autopsy on Case 13 showed a fresh infarct in the pons and old cerebellar infarcts. There was thrombosis within the ectatic vessel.
Discussion
The initial event in the formation of fusiform aneurysm is thought to be lipid deposition in and beneath the intima that disrupts the internal elastic membrane and infiltrates the muscular wall. 1 
The resultant atrophy of the elastic substance and the musculature then leads to tortuosity of the vessel due to intravascular pressure, 4 -612 causing the ectatic vessel to expand in diameter and length. Unlike the focal outpouchings found in saccular aneurysms, in fusiform aneurysms the entire vessel expands, which supports the observation that deficiency of the muscular wall and internal elastic lamina is diffuse. The circulation slows because of this increased luminal diameter, and the resulting turbulent blood flow predisposes the vessel to thrombosis, which promotes further intimal disruption and vessel distortion.
-
8 Repeated thrombosis near the wall makes the vessel stiff and thick. The natural tendency then for a fusiform aneurysm is to expand and produce mass effects on nearby structures. Or, the expanding fusiform aneurysm can distort vascular branches, reducing distal flow, or can even serve as a nidus for clot formation and distant embolization. - 16 The risk of rupture of the fusiform aneurysm and hemorrhage is reduced due to the diffusely thickened and stiff wall. The initial presentation of sixth nerve palsy due to mass effect and finally brainstem infarction in Case 1 illustrates the sequelae.
The clinical features of fusiform aneurysm have been studied by various investigators, 7 ' 8 who divided them into three categories: ischemic; cranial nerve compression; and "pseudotumoral," when the fusiform aneurysm compresses vital structures other than cranial nerves. No hemorrhage due to rupture of vertebrobasilar fusiform aneurysm was reported in their series. Yu et al 9 studied 17 cases of vertebrobasilar fusiform aneurysm and found nine with brainstem ischemia and six with compressive symptoms. In addition, Yu et al 9 also found three cases of subarachnoid hemorrhage (SAH), one from an associated saccular aneurysm of the anterior communicating artery and two with concomitant carotid fusiform aneurysm. The other two patients may have bled from a concomitant carotid fusiform aneurysm since there is evidence that they are more prone to bleed than are vertebrobasilar fusiform aneurysms. 12 Nishizaki et al 5 studied 23 cases of vertebrobasilar fusiform aneurysm and divided the initial symptoms into ischemic and mass effects. Intracranial hemorrhage was described in only three patients, one of whom experienced a hypertensive cerebellar hemorrhage; the other two patients had saccular aneurysmal hemorrhages.
Recently, Pessin et al 10 reported seven patients with brainstem infarctions with vertebrobasilar fusiform aneurysms. The mechanisms of infarction were described as intraluminal thrombosis, local -10 in addition to our current series, indicate the rarity of hemorrhage in vertebrobasilar fusiform aneurysm. We saw compressive symptoms in four and ischemic symptoms in 10 patients; one patient exhibited both types of symptoms. Hemorrhage, which appeared to be unrelated to the fusiform aneurysm because of its location and a history of hypertension, was seen in only one patient (Case 3).
Compression of nearby structures has also been described in single case reports.

17
- 18 Four patients in our series presented with such symptoms. The thalamic infarct in Case 12 represented ischemia due to distant embolization from the vertebrobasilar fusiform aneurysm, illustrated by the MRI findings showing a dilated vessel and an infarct in the thalamus (Figure 3) .
The duration of symptoms before the diagnosis of fusiform aneurysm varied depending upon the type of symptoms. A longer duration was seen in patients presenting with compressive symptoms than in those presenting with ischemic symptoms. Similar results were observed by Boeri and Passerini. 6 It is possible that the delay between onset of symptoms and diagnosis among patients with compressive symptoms is due to the time taken for the fusiform aneurysm to slowly enlarge and produce compression. While there appears to be a consensus on the pathophysiologic mechanisms of vertebrobasilar fusi- form aneurysm, there is no general agreement regarding the treatment, nor have consistently successful results been reported in the literature. In the study of Yu et al, 9 two of nine patients with ischemia were treated with anticoagulants. All seven untreated patients died of progressive brainstem ischemia, but the two anticoagulated patients were alive at the 10-year follow-up. The overall mortality in that series was 63%. Those patients with compressive symptoms went on to develop brainstem ischemia or a progressive mass effect due to the fusiform aneurysm. Nishizaki et al 5 suggested the use of antiplatelet therapy in all patients with vertebrobasilar fusiform aneurysm, even those without ischemic symptoms. No follow-up of their patients is available.
In our series, seven patients treated with anticoagulants remained alive for a mean of 18 months, with residual neurologic deficits but without any recurrence of their symptoms. In one of these patients, when anticoagulation was stopped for cataract surgery, the symptoms recurred. After resuming anticoagulation, no further recurrence had occurred at 36 months follow-up.
Although antiplatelet therapy has been used to prevent thrombosis and embolization, our data show that despite receiving this therapy, four of nine patients went on to develop ischemic symptoms that required switching to anticoagulation. Of the remaining five patients, four died, three of progressive brainstem infarction. Since rupture and hemorrhage are rare, these results show a more favorable outcome of vertebrobasilar fusiform aneurysm with anticoagulation therapy. Although ours was not a controlled or double-blind study, it is a relatively large series of cases with retrospective analysis that suggests that anticoagulation is perhaps better than antiplatelet therapy. However, without a properly controlled, randomized, and long-term study, no definite recommendations can be reasonably proposed at this time.
Hemorrhage, either due to rupture of the vertebrobasilar fusiform aneurysm or as a complication of anticoagulation, was not seen at all in our study; neither was it reported in the series of Yu et al 9 or Nishizaki et al. 5 Whenever hemorrhage was seen in those patients, a separate cause, such as concomitant saccular aneurysm, carotid fusiform aneurysm, or uncontrolled hypertension, was evident.
